ASLN — ASLAN PHARMACEUTICALS LT ADR
什么是 13F 持仓报告?谁需要申报、何时申报 · 13F 持仓报告看不到什么
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
截至Q2 2026,共 1 家机构在其最新 13F 申报中持有 ASLN(ASLAN PHARMACEUTICALS LT ADR),合计申报市值 $17,对应 29 股。按股数计算较上季度增持 0.0%(+0 股),申报市值环比上升 0.0%。持仓集中度较高:前五大持有人占申报市值的 100.0%,前十大的集中度为 100.0%。
ASLAN PHARMACEUTICALS LT ADR(ASLN)的主要机构持有人包括 TANG CAPITAL MANAGEMENT LLC、Vivo Capital, LLC、BVF INC/IL,按 13F 申报市值在本页 35 家持有人中排名居前。
本页所有数据均来自美国证监会(SEC)13F 季度申报。13F 申报人需在季度结束后 45 天内披露 10 万美元以上的多头持仓;空头、期权对冲与季度内交易不在其列,因此这些数字反映的是机构持仓的季度快照,而非实时仓位。
机构逐季持仓趋势
| 季度 | 持有机构数 | 股数 | 金额 | 环比净变动 |
|---|---|---|---|---|
| Q3 2026 | 1 | 29 | $17 | +0.0% |
| Q2 2026 | 1 | 29 | $17 | +0.0% |
| Q1 2026 | 1 | 29 | $17 | +0.0% |
| Q4 2025 | 1 | 29 | $17 | +0.0% |
| Q3 2025 | 1 | 29 | $17 | -71.3% |
| Q2 2025 | 1 | 101 | $60 | -36.9% |
| Q1 2025 | 1 | 160 | $95 | +0.0% |
| Q4 2024 | 1 | 160 | $95 | +0.0% |
表内 8 个季度中,机构持股合计减少 82%(Q4 2024 → Q3 2026);单季变动最大的是 Q3 2025(-71.3%)。
更早季度的机构持仓记录(逐季列表): 返回前 25 大机构持仓人
Q2 2026 — 1 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 29 | $17 | 0.00% | 持有 |
Q1 2026 — 1 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 29 | $17 | 0.00% | 持有 |
Q4 2025 — 1 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 29 | $17 | 0.00% | 持有 |
Q3 2025 — 1 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 29 | $17 | 0.00% | 减持 |
Q2 2025 — 1 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 101 | $60 | 0.00% | 减持 |
新建仓(Q2 2026)
本季度没有基金新建该仓位。
完全清仓(较上季)
本季度没有被追踪基金完全清仓。
基金持仓历史 — 各季度股数(前 20 只基金)
| 基金 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RHUMBLINE ADVISERS | 29 | 29 | 29 | 29 | 29 | 101 | 160 | 160 | 160 | 1.29K | 1.29K | 1.29K | 1.29K | — | — | — | — | — | — | — |
| TANG CAPITAL MANAGEMENT LLC | — | — | — | — | — | — | — | — | — | — | — | — | 1.90M | — | — | — | — | — | — | — |
| BVF INC/IL | — | — | — | — | — | — | — | — | — | 1.05M | 1.05M | 1.05M | 1.05M | — | — | — | — | — | — | — |
| Velan Capital Investment Management LP | — | — | — | — | — | — | — | — | — | 625.00K | 625.00K | — | 625.00K | — | — | — | — | — | — | — |
| Vivo Capital, LLC | — | — | — | — | — | — | — | — | — | — | — | — | 568.18K | — | — | — | — | — | — | — |
| Parkman Healthcare Partners LLC | — | — | — | — | — | — | — | — | — | — | — | 110.66K | 372.74K | — | — | — | — | — | — | — |
| Temasek Holdings (Private) Ltd | — | — | — | — | — | — | — | — | — | — | — | 15.68K | 335.62K | — | — | — | — | — | — | — |
| Sio Capital Management, LLC | — | — | — | — | — | — | — | — | — | 254.15K | 254.15K | 254.15K | 254.15K | — | — | — | — | — | — | — |
| UBS Group AG | — | — | — | — | — | — | — | — | — | 16.44K | — | 625.00K | — | 100 | — | 2.22K | 1.60K | — | 6.37K | — |
| Shay Capital LLC | — | — | — | — | — | — | — | — | — | 400.00K | 400.00K | 400.00K | — | — | — | — | — | — | — | — |
| Renaissance Technologies | — | — | — | — | — | — | — | — | — | 138.86K | 122.50K | 172.80K | 33.46K | 28.76K | 41.00K | 262.51K | 365.80K | 475.90K | 70.60K | — |
| Schonfeld Strategic Advisors LLC | — | — | — | — | — | — | — | — | — | 124.30K | 147.40K | 27.70K | 91.50K | — | — | — | — | — | — | — |
| MILLENNIUM MANAGEMENT LLC | — | — | — | — | — | — | — | — | — | 46.37K | 39.64K | 80.36K | 80.46K | — | — | — | — | — | — | — |
| Citigroup Inc | — | — | — | — | — | — | — | — | — | — | — | — | 58.00K | 58.00K | 58.00K | 290.00K | — | — | — | — |
| Waterfront Wealth Inc. | — | — | — | — | — | — | — | — | — | 22.72K | 20.72K | 40.94K | 49.44K | — | — | — | — | — | — | — |
| Morgan Stanley | — | — | — | — | — | — | — | — | — | 8.70K | 8.70K | 24.70K | 28.96K | 28.96K | 30.16K | 150.79K | 150.98K | 254.95K | 496.97K | 250.82K |
| Marex Group Ltd | — | — | — | — | — | — | — | — | — | 83.46K | 83.36K | — | — | — | — | — | — | — | — | — |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | — | — | — | — | — | — | — | — | — | — | — | 83.26K | — | — | — | — | — | — | — | — |
| ADAR1 Capital Management, LLC | — | — | — | — | — | — | — | — | — | — | 59.39K | — | — | — | — | — | — | — | — | — |
| FNY Investment Advisers, LLC | — | — | — | — | — | — | — | — | — | — | 46.70K | — | — | — | — | — | — | — | — | — |
常见问题
Which funds hold ASLN?
As of 2026-Q2, 1 institutional funds reported holding ASLN (ASLAN PHARMACEUTICALS LT ADR) in SEC 13F filings, with a combined reported value of $17.
How many shares of ASLN do institutions own?
13F filers reported 29 shares of ASLN, worth $17 in aggregate at the end of 2026-Q2.
Is institutional ownership of ASLN rising or falling?
Share counts moved +0.0% versus the prior quarter — accumulation.
Who are the top institutional holders of ASLN?
The largest 13F holders are TANG CAPITAL MANAGEMENT LLC, Vivo Capital, LLC, BVF INC/IL, Velan Capital Investment Management LP, Shay Capital LLC; the top 25 are ranked at the top of this page.
Who are the major shareholders of ASLAN PHARMACEUTICALS LT ADR?
The major shareholders of ASLAN PHARMACEUTICALS LT ADR (ASLN) by reported 13F value are TANG CAPITAL MANAGEMENT LLC, Vivo Capital, LLC, BVF INC/IL, Velan Capital Investment Management LP, Shay Capital LLC, among 35 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.